Search results: marta irigoyen

Inactivation of tumor suppressor genes (TSGs) confers a cellular fitness advantage to human cancer cells, including in acute myeloid leukemia (AML), where it disrupts myeloid differentiation and promotes leukemogenesis. Loss-of-function mutations in TSGs are frequently observed in patients with hematologic malignancies , driving disease progression by blocking differentiation and enhancing self-renewal. Therefore, restoration of tumor […]

Chimeric antigen-specific receptor (CAR) T-cell immunotherapy targeting B-cell maturation antigen (BCMA; BCMA-CAR T cells) has produced remarkable clinical responses in advanced multiple myeloma (MM), with a substantial fraction of patients achieving complete remission . However, many patients relapse within months, largely due to insufficient CAR T-cell persistence, a recognized mechanism of acquired resistance . A […]

T-cell acute lymphoblastic leukemia (T-ALL) and T-cell acute lymphoblastic lymphoma (T-LBL) are aggressive hematological malignancies that arise from abnormal activation of oncogenes and/or inactivation of tumor-suppressor genes, followed by a differentiation arrest and uncontrolled clonal expansion of immature thymocytes . Proviral integration site for Moloney-murine leukemia 1 (PIM1) is a known JAK-STAT target gene that […]

T-cell lymphoblastic lymphoma (T-LBL) is a precursor T cell lymphoma. T-LBL represents the second most common subtype of Non-Hodgkin lymphoma in both children and adolescents; however, it is less common in adults . T-LBL share many characteristics with the precursor T cell leukemia (T-ALL), however, various studies have indicated that T-ALL and T-LBL might be […]

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a poor prognosis and limited options for targeted therapies . Since the targeted therapies benefiting T-ALL are still limited owing to the biological heterogeneity of T-ALL , identifying novel “druggable” molecular markers and illustrating the underlying mechanisms are immediate pressing issues in T-ALL […]

Acute myeloid leukemia (AML) with t(6;9)/DEK::NUP214 is recognized as a separate entity in the World Health Organization classification of myeloid neoplasms, accounting for 1% of all AML cases and characterized by a high relapse rate and young age at diagnosis . The t(6;9) chromosomal rearrangement results in the fusion of almost the entire peptide sequence […]

T-cell acute lymphoblastic leukemia (T-ALL) is characterized by the accumulation of genetic lesions that induce differentiation arrest, survival and aberrant proliferation of immature T-cell progenitors . Although T-ALL prognosis has significantly improved due to intensive chemotherapy, relapses still occur in 20% of pediatric patients and 50% of adult patients, often with a dismal outcome. To […]

Acute myeloid leukemia (AML) is a hematological malignancy arising from the occurrence of genetic mutations in hematopoietic progenitors, which cause a blockage in the maturation and an uncontrolled growth of leukemic blasts in the bone marrow (BM). The resistance to current therapies and relapse remain a major clinical challenge. For this reason, a novel approach […]

Multiple myeloma (MM) is an incurable hematological malignancy characterized by clonal expansion of plasma cells in the bone marrow (BM) . Nearly 90% of myeloma patients suffer from skeletal-related events during the course of the disease that not only affect the quality of life but also their overall survival . Myeloma-associated bone disease (MBD) is […]

Acute myeloid leukemia (AML) is a disease of older persons that has a dismal outcome and patients unfit for intensive chemotherapy exhibit a median survival of only 5 to 10 months . However, the therapeutic landscape of AML is changing with the appearance of new-targeted drugs such as BH3 mimetics that inhibit prosurvival BCL2 family […]